Skip to main content

Table 1 (Abstract A22). Efficacy outcomes measures at the end of the first year of the OLEP, Observed (Open-Label Analysis Set)

From: 13th European Headache Federation Congress 2019 - Abstracts

OutcomesValues at Week 64 (Week 52 of OLEP)
 Patients on erenumab 140 mg continued on erenumab 140 mg in the OLEP, N=118Patients on placebo who initiated erenumab 140 mg in the OLEP, N=122Overall population, N=240
≥50% reduction in MMD44.3%50.0%47.1%
≥75% reduction in MMD21.4%25.8%23.5%
100% reduction in MMD8.6%16.7%12.5%
Change from the DBTP baseline in MMD−3.8 (3.9)−3.6 (4.4)−3.7 (4.1)
Change from the DBTP baseline in HIT-6−8.5 (7.4)−9.7 (10.0)−9.0 (8.7)
Change from the DBTP baseline in MPFID-PI−5.2 (6.9)−4.5 (8.4)−4.8 (7.7)
Change from the DBTP baseline in MPFID-EA−6.6 (7.7)−5.1 (9.4)−5.9 (8.6)
  1. Data are mean (SD) or % of the patients with non-missing value at Week 64; Data for HIT-6 reported at Week 60.
  2. DBTP, double-blind treatment phase; HIT-6, Headache Impact Test; MMD, monthly migraine days; MPFID-EA; Migraine Physical Function Impact Diary-everyday activities MPFID-PI, Migraine Physical Function Impact Diary-physical impairment; N, number of subjects included in the analysis set; OLEP, open-label extension phase; SD, standard deviation
\